Company Overview - Tactile Systems Technology (TCMD) shares have increased by 31% over the past month, reaching a new 52-week high of $19.55 [1] - The stock has gained 32.3% year-to-date, outperforming the Zacks Medical sector's 1% and the Zacks Medical - Instruments industry's 5.3% returns [1] Earnings Performance - TCMD has a strong record of positive earnings surprises, not missing earnings consensus estimates in the last four quarters [2] - In the latest earnings report on November 4, 2024, TCMD reported EPS of $0.24, exceeding the consensus estimate of $0.18 [2] Financial Projections - For the current fiscal year, TCMD is expected to post earnings of $0.65 per share on revenues of $292.84 million, reflecting a -48.03% change in EPS and a 6.71% change in revenues [3] - For the next fiscal year, earnings are projected to be $0.86 per share on revenues of $322.36 million, indicating a year-over-year change of 31.44% in EPS and 10.08% in revenues [3] Valuation Metrics - TCMD currently trades at 28.9X current fiscal year EPS estimates, slightly above the peer industry average of 28.8X [7] - On a trailing cash flow basis, the stock trades at 12.3X compared to the peer group's average of 17.3X [7] Zacks Rank and Style Scores - TCMD holds a Zacks Rank of 2 (Buy) due to favorable earnings estimate revisions from analysts [8] - The stock has a Value Score of A, with Growth and Momentum Scores of C, resulting in a combined VGM Score of B [6][9] Industry Comparison - Fresenius Medical Care AG & Co. KGaA (FMS) is a notable peer with a Zacks Rank of 2 (Buy) and similar style scores [10] - FMS is expected to post earnings of $1.87 per share on revenues of $21.02 billion for the current fiscal year, having beaten consensus estimates by 7.14% last quarter [11] - The Medical - Instruments industry is performing well, ranking in the top 25% of all industries, providing favorable conditions for both TCMD and FMS [12]

MINNEAPOLIS, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will participate in the Piper Sandler 36th Annual Healthcare Conference, which is being held at the Lotte New York Palace in New York, NY from December 3rd – 5th. Management will participate in a fireside chat on Tuesday, December 3rd at 10:00 a.m. Central Time. A ...

Tactile Systems Technology (TCMD) is a Zacks Rank #2 (Buy) that has an A for Value and a C for Growth.  The company develops medical devices for the treatment of chronic diseases at home. Let’s explore more about this company in this Bull of The Day article.DescriptionTactile Systems Technology, Inc. engages in developing and providing medical devices for the treatment of underserved chronic diseases. It provides lymphedema solutions and offers Flexitouch Plus and Entre Plus systems products. The company wa ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the ...

Shares of Tactile Systems Technology (TCMD) have gained 3.1% over the past four weeks to close the last trading session at $14.62, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $21.33 indicates a potential upside of 45.9%.The average comprises three short-term price targets ranging from a low of $16 to a high of $25, with a standard deviation of $4.73. While the lowest estimat ...

Tactile Systems Technology (TCMD) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.85 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 33.33%. A quarter ago, it was expected that this medical device maker would post earnings of $0.10 per share when it actually produced earnings of $0.20, delivering a surprise of 100%.Over the last four ...

MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the third quarter ended September 30, 2024 and announced the adoption of a share repurchase program. Third Quarter 2024 Summary & Recent Business Highlights: Total revenue increased 5% year-over-year to $73.1 million Lymphedema product revenue increased 4% ove ...

MINNEAPOLIS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that third quarter of fiscal year 2024 financial results will be released after the market closes on Monday, November 4, 2024. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on November 4, 2024, to discuss the results of the qua ...

MINNEAPOLIS, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the publication of a new clinical study in the Journal of Vascular Surgery, Venous and Lymphatic Disorders. This study assessed outcomes associated with use of the Company's Flexitouch advanced pneumatic compression device (APCD) in Veterans with lower extremity lymphedema. Notab ...

Shares of Tactile Systems Technology (TCMD) have gained 13.7% over the past four weeks to close the last trading session at $13.14, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $20.67 indicates a potential upside of 57.3%. The mean estimate comprises three short-term price targets with a standard deviation of $4.04. While the lowest estimate of $17 indicates a 29.4% increase ...